Guardant Health raises 2026 revenue guidance to $1.34-$1.36 bln, up from $1.30-$1.32 bln
Company expects 2026 screening revenue of $218-$230 mln, driven by Shield volume of 270,000-285,000 tests
Guardant Health sees 2026 non-GAAP gross margin at 64%-65%
Overview
US precision oncology firm's Q2 revenue rose 44%, beating analyst expectations
Adjusted loss per share for Q2 slightly missed analyst estimates
Company raised 2026 revenue guidance on strong Shield screening growth and FDA approvals
Result drivers
Oncology volume - Oncology revenue rose 38%, driven mainly by a 63% increase in oncology test volume
Shield screening - Screening revenue grew over 250%, driven by Shield test volume rising to 66,000 from 16,000 in the prior year
FDA approvals & coverage - Recent FDA approvals and expanded insurance coverage for Shield supported growth, according to co-CEOs
Analyst coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 25 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"
GH•
